Comparing the B and T cell-mediated immune responses in patients with type 2 diabetes receiving mRNA or inactivated COVID-19 vaccines
Immunity, Cellular
0303 health sciences
COVID-19 Vaccines
SARS-CoV-2
Immunology
COVID-19
Viral Vaccines
RC581-607
3. Good health
immunological memory response
03 medical and health sciences
Diabetes Mellitus, Type 2
Immunoglobulin G
Humans
RNA, Viral
CoronaVac
BNT162b2
type 2 diabetes
RNA, Messenger
Immunologic diseases. Allergy
COVID-19 vaccine
BNT162 Vaccine
DOI:
10.3389/fimmu.2022.1018393
Publication Date:
2022-10-11T08:30:20Z
AUTHORS (11)
ABSTRACT
Acquiring protective immunity through vaccination is essential, especially for patients with type 2 diabetes who are vulnerable adverse clinical outcomes during coronavirus disease 2019 (COVID-19) infection. Type (T2D) associated immune dysfunction. Here, we evaluated the impact of T2D on immunological responses induced by mRNA (BNT162b2) and inactivated (CoronaVac) vaccines, two most commonly used COVID-19 vaccines. The study consisted parts. In Part 1, sera titres IgG antibodies against severe acute respiratory syndrome (SARS-CoV2) alpha receptor binding domain ( RBD), their neutralizing capacity, antigen-specific CD4 + T CD8 cell at 3-6 months after were compared between BNT162b2 (n=60) CoronaVac (n=50) vaccinees or without T2D. was a time-course investigating initial B among (n=16) Our data showed that impaired both cellular humoral CoronaVac. For BNT162b2, displayed reduction in T-helper 1 (Th1) differentiation following first dose. However, this defect rectified second dose resulting comparable levels memory cells, anti-RBD IgG, healthy individuals vaccination. Hence, influences effectiveness vaccines depending platform. findings provide potential mechanism susceptibility developing observed received either just one BNT162b2.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (48)
CITATIONS (19)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....